cystic fibrosis

Antibiotic resistance is on the rise and scientists are on the lookout for new therapeutics for treating human pathogens. One promising new venture repurposes antimalarial drugs to treat patients with chronic lung diseases such as cystic fibrosis.

People with cystic fibrosis seem resistant to COVID-19. Researchers developed a culture system to interrogate the mechanism behind it.

Ultra-microscopic viruses that selectively target and kill bacteria may mitigate antimicrobial resistance.

AzurRx completes enrollment in Phase 2 clinical trial of MS1819 in combination with PERT to treat cystic fibrosis patients with severe exocrine pancreatic insufficiency